Radiation vs. BCG for high-risk bladder cancer
Treatments studied
Part of Cancer, Kidney & urinary, Women’s health & pregnancy clinical trials.
This trial compares radiotherapy with a radiosensitizer to BCG therapy for people with high-risk non-muscle invasive bladder cancer. The goal is to see which treatment better controls the cancer and helps patients avoid bladder removal.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a type of bladder cancer called high-risk non-muscle invasive bladder cancer
- You are fit enough to receive either BCG therapy or radiation treatment
- Your doctor expects you to live at least another year
- You are 16 years or older
- You have not had radiation to the pelvic area before
- You have not had prior treatment inside the bladder (like BCG or chemotherapy)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether radiation therapy can help people whose bladder cancer (specifically carcinoma in situ) did not get better with BCG treatment and who are not having their bladder removed. It aims to offer a less invasive option for controlling the cancer.
This trial tests radiotherapy (high-energy X-rays) for a specific type of early-stage bladder cancer (CIS) that hasn't gone away after BCG treatment. It's for people who can't or choose not to have bladder removal surgery.
This trial tests if a special type of tumor removal (ERBT) followed by BCG immunotherapy is better than standard treatment for medium- or high-risk non-muscle-invasive bladder cancer. It may help people whose bladder cancer has come back, has multiple tumors, or has a tumor larger than 1 cm.
This trial studies a BCG-based bladder instillation in people with newly diagnosed, intermediate- or high-risk non-muscle invasive bladder cancer who have had their tumor fully removed. The goal is to see whether this treatment is safer and works better to lower the chance of the cancer coming back.
This study is testing whether a urine or blood test can help guide BCG treatment for high-risk bladder cancer that hasn't spread into the muscle. It is only for people over 65 who are new to BCG therapy.
This trial tests a combination of two treatments after bladder tumor surgery: a drug called toripalimab (given through a vein) plus BCG therapy (given into the bladder) for people with high-risk non-muscle-invasive bladder cancer. The goal is to see if this combination can help prevent the cancer from coming back.
Hear when a new High Risk Non-muscle Invasive Bladder Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.